Background Acute respiratory distress syndrome (ARDS) is the most severe form of lung injury, rendering gaseous exchange insufficient, leading to respiratory failure. Despite over 50 years of research on the treatment of ARDS when developed from illnesses such as sepsis and pneumonia, mortality remains high, and no robust pharmacological treatments exist. The progression of SARS-CoV-2 infections to ARDS during the recent global pandemic led to a surge in the number of clinical trials on the condition. Understandably, this explosion in new research focused on COVID-19 ARDS (CARDS) rather than ARDS when developed from other illnesses, yet differences in pathology between the two conditions mean that optimal treatment for them may be distinct.
Aim The aim of the present work is to assess whether new therapeutic interventions that have been developed for the treatment of CARDS may also hold strong potential in the treatment of ARDS when developed from other illnesses. The study objectives are achieved through a systematic review of clinical trials.
Results The COVID-19 pandemic led to the identification of various therapeutic interventions for CARDS, some but not all of which are optimal for the management of ARDS. Interventions more suited to CARDS pathology include antithrombotics and biologic agents, such as cytokine inhibitors. Cell-based therapies, on the other hand, show promise in the treatment of both conditions, attributed to their broad mechanisms of action and the overlap in the clinical manifestations of the conditions. A shift towards personalised treatments for both CARDS and ARDS, as reflected through the increasing use of biologics, is also evident.
Conclusions As ongoing CARDS clinical trials progress, their findings are likely to have important implications that alter the management of ARDS in patients that develop the condition from illnesses other than COVID-19 in the future.
- Respiratory Infection
Data availability statement
Data are available in a public, open access repository.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
WHAT IS ALREADY KNOWN ON THIS TOPIC
The COVID-19 pandemic led to a huge increase in clinical trials on patients with acute respiratory distress syndrome (ARDS). ARDS developed from COVID-19 and from other illnesses have distinct pathologies, with dysregulated immune responses in the former, leading to hyperinflammation and cytokine storms.
WHAT THIS STUDY ADDS
The systematic review evaluates the potential of novel therapeutic interventions developed for COVID-19 ARDS in the treatment of ARDS when developed from other illnesses. It is shown that complement system modifiers, cell-based therapies and biologics hold clear potential.
HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY
It is hoped that the outcome will focus future clinical research on these interventions with potential benefits for patients with a range of conditions, including pneumonia and sepsis.
The COVID-19 pandemic has shone light on the inadequate treatment options for acute respiratory distress syndrome (ARDS). Within the United Kingdom (UK), 12.5% of intensive care unit admissions meet ARDS criteria,1 and in the United States of America (USA), ARDS affects around 150 0002 3 to 200 0004 people annually. ARDS is the most severe form of acute lung injury (ALI)2 5 6 and is characterised by inflammatory damage to the alveolar-capillary membrane, increasing capillary permeability,7–11 leading to oedema in the alveoli and lung interstitium.7 11 The initial damage can be direct via pneumonia, pulmonary infection or aspiration, or indirect via sepsis, drug toxicity, blood transfusions or non-pulmonary major trauma.7–9 11 12 Following activation of a local inflammatory response, the release of proinflammatory cytokines promotes further damage to the lungs.6–10 12
The resulting decrease in efficacy and capacity for gaseous exchange13 14 is worsened by alveolar atelectasis.5 7 11–15 Where ARDS has advanced to the fibrotic stage,16 17 surfactant production is impeded, encouraging atelectasis.5 7–9 11–15 Despite physiological attempts to correct hypoxemia and hypercapnia presenting as dyspnoea, the condition deteriorates to refractory hypoxemia and respiratory failure, necessitating mechanical ventilation (MV).2 18–20 MV incurs additional risks, including ventilator-induced lung injury (VILI) (eg, barotrauma),5 10 21 and an increased risk of nosocomial infections, particularly ventilator-associated pneumonia.20 Prolonged MV increases the incidence of neuromuscular dysfunction, potentially triggering multiple-organ dysfunction.20 Other ARDS complications include mood disturbances16 20 and organ dysfunction or failure.22 The leading cause of death is multiorgan failure,1 8 10 20 22 followed by thromboembolic complications22 and sepsis.20
The widely heterogenous nature of ARDS has contributed to a lack of effective pharmacological treatments, although identifying the initial clinical insult can aid the selection of therapies.8 9 Neuromuscular blocking agents (NMBAs) boost the lung and chest wall compliance, improving patient-ventilator synchrony and the extent of hypoxaemia, reducing oxygen consumption and the risk of VILI. In patients with severe ARDS, early administration of an NMBA for 48 hours improved patient survival and reduced ventilator dependence without causing muscle weakness.23 However, neuromuscular weakness can develop with their prolonged use, resulting in difficulties weaning patients off MV.10 19 Vasodilators are hypothesised to improve gaseous exchange relieving severe hypoxia, but therapy needs to be kept short term,10 12 and it is accepted that there is no mortality benefit.24 Bronchodilators may prevent worsening of alveolar-capillary permeability, helping to prevent further existing oedema, alongside offering potential anti-inflammatory effects,10 13 but studies have shown that they can be ineffective or even harmful in the treatment of ARDS.25–27 Glucocorticoids reduce inflammation and improve oxygenation and MV duration, but no significant changes in mortality rates have been reported, and their immunosuppressive actions may prolong viral replication.10 12 18 19 22 28 Despite the reported pleiotropic anti-inflammatory and antiproliferative effects of statins, their clinical benefit in ARDS remains inconsistent.16 18 29 Although surfactants do not improve mortality or MV duration in ARDS, they are thought to improve the mechanical properties of alveoli and, therefore, benefit CARDS patients, where clinical presentation is similar to infantile respiratory distress syndrome in which surfactants are routinely used.15 16 18 Alternative approaches include novel therapeutics such as mesenchymal stem cells (MSCs), which release bioactive factors promoting repair of injured lung tissue.16 However, despite the wide range of therapeutics available, morbidity and mortality rates remain high.
COVID-19-induced ARDS (CARDS) is the most severe clinical manifestation following infection with the SARS-CoV-2 virus.30 Soon after the start of the pandemic, and prior to global vaccination drives, COVID-19 infection became the most common cause of ARDS worldwide, with cases doubling in the USA,31 causing a marked increase in demands on healthcare services and ventilators worldwide and emphasising the need for new treatments.31–33
CARDS was initially managed similarly to ARDS,34 yet their differing pathologies mitigate the effectiveness of ARDS treatments in CARDS.35–39 In CARDS, dysregulated immune responses30 38 40 cause exaggerated increases in immune cells and inflammatory markers, particularly in severe COVID-19 infections,30 38 40 41 leading to hyperinflammation38 40 42 and cytokine storms.32 38 40–44 Cytokine storms, which are also observed in ARDS, are considered to be the main cause of CARDS45 and are linked to its progression with cytokine-neutralising agents, including interleukin-6 (IL-6) and IL-6 receptor inhibitors being used to clinical benefit.38 40 CARDS is more likely to require longer MV durations30 32 33 and potentially a higher VILI frequency,43 46 since prolonged MV is associated with persistently raised immune cells.30 Furthermore, CARDS has a higher incidence of intravascular thrombosis and other thromboembolic manifestations,31 39 which may be due to coagulation dysfunction.39 The distinctive clinical features of the conditions are summarised in table 1.
The COVID-19 pandemic has stimulated a rapid expansion in the number of clinical trials (CTs) assessing new interventions for CARDS. This presents a unique opportunity to evaluate whether new treatments initially developed for CARDS hold potential for use in the treatment of ARDS developed from other illnesses. The overarching aim of this study is to assess the potential of interventional treatments for CARDS in the treatment of ARDS from other illnesses through a systematic review of CTs on therapeutic interventions for ARDS and CARDS in the USA and UK. Highly valuable reviews have been published recently on a comparison of ALI in COVID-19 and non-COVID-19 patients,47 on the epidemiology of ARDS before and after pandemic,48 on current treatment for CARDS patients32 and on how atypical CARDS is in comparison with ARDS.49 However, to the knowledge of the authors, the present review represents the first with a scope to learn what strategies from the vigorous development of CARDS treatments hold potential for use in the treatment of ARDS from other illnesses.
This retrospective, observational, systematic review of CTs was undertaken using the database ClinicalTrials.gov, which is provided by the US National Library of Medicine. This database was chosen because it includes publicly and privately funded research studies, allowing a comprehensive view of treatments being investigated.
All searches were carried out between 4 and 9 March 2022 using the search term ‘acute respiratory distress syndrome’ under the ‘condition or disease’ field, and ‘drug’ under the ‘other terms’ field, which identified 711 studies (figure 1A). This search was kept deliberately broad in order to include all related studies in the results, even if referred to in the title using synonyms of the conditions, including ALI.
Restriction of the data set to include only interventional studies reduced the number of trials to 570 (figure 1B). This step excluded studies that were expanded access or compassionate use, observational or behavioural, as they did not assess administration of a pharmacological agent.
Search criteria were further modified by selecting only ‘adult (18–64)’ and ‘older adult (65+)’ to ensure only participants aged 18 years or over were included, identifying 449 CTs (figure 1C); there are differences in disease pathophysiology between adults and children, and a low incidence and severity of CARDS in children.
The search was then refined to include only CTs from the USA or UK, yielding 169 and 23, respectively (figure 1D); these countries have two of the largest and most highly regulated healthcare systems in the world, with comparable high expenditures on services and infrastructure.50
CTs were manually screened and filtered to ensure that all eligible examples were identified. Studies were deemed relevant from their title, conditions treated and intervention(s) prescribed. Each CT was then thoroughly inspected to ensure that participants met the criteria either for ARDS alone (using the EACC criteria16 28 51 or Berlin definition criteria18 28) or for both ALI or ARDS and were interventional, so they involved administration of a pharmacological agent. The following exclusion criteria were applied to eliminate irrelevant CTs:
Application of intervention for ARDS was not assessed or ARDS was not listed as a condition under investigation (29 USA and 3 UK).
Participants did not meet the criteria for ALI or ARDS diagnosis (29 USA and 3 UK).
Behavioural or mechanical interventions were assessed (28 USA and 4 UK).
Paediatric participants were involved (11 USA).
Healthy participants were involved (5 USA and 5 UK).
Pregnant or recently postpartum participants were involved (5 USA).
The investigational agent was used as a marker in an exploratory investigational trial (1 UK)
This refinement process identified 61 and 7 CTs from the USA and UK databases, respectively (figure 1E), before two CTs were eliminated due to duplication. This gave a total of 66 CTs for analysis (figure 1F), which are listed numerically by CT number (for ease of reference) in the Electronic Supporting Information.
Patient and public involvement
No patients were involved in this study.
Overview of the CT metrics data
The CTs assessing new therapies for CARDS and ARDS were first categorised by the year in which they started (figure 2A). The number of ARDS CTs starting per year was typically 1–3, with a peak of 5 in 2009, yet the number stayed comparatively steady even throughout the pandemic. Strikingly, there was a significant increase in the number of CTs following the emergence of COVID-19. The number of CARDS CTs peaked at 22 starting in 2020, and then fell by more than half to 7 starting in 2021; the further drop in 2022 should be viewed with caution given that the present study took place in March 2022. Interestingly, over the whole period, there was the same number of CTs starting to investigate treatments for CARDS as for ARDS (n=33), and at the time of the study, 20 CTs had results published on ClinicalTrials.gov. One CARDS CT is shown as starting in 2018 (NCT03376854), which may at first seem anomalous, but the study shifted its focus from ARDS to CARDS as the COVID-19 pandemic transpired.
The phase of the CTs in March 2022 was next considered both for ARDS (figure 2B) and CARDS (figure 2C). As CARDS is a recent condition, there was a higher proportion of CARDS CTs in earlier phases than ARDS CTs, and fewer were completed with published results (n=6 vs 14, respectively). Many CTs were in their early stages: 41% measured adverse events of the interventions to assess safety in at least one of their primary outcomes, where an adverse event, in the context of a CT, is any untoward or unfavourable medical occurrence, including but not limited to an abnormal physical examination, abnormal laboratory finding, a symptom or disease, medication side effects, injury, psychological harm or trauma or death. Other primary and secondary outcomes assessed include 38% on mortality, 30% on MV duration, 9% on oxygenation, most commonly through the PaO2/FiO2 ratio, and 9% on a clinical biomarker specific to the intervention to assess its pharmacodynamic effect, for example, four CTs measured IL-6 or IL-8 concentrations as common inflammatory biomarkers.
Both ARDS and CARDS CTs assessed a range of clinical outcomes with the number of primary outcomes per CT shown (figure 3A). Of the CTs with primary outcomes, 65% had only one while 23% had two; commonly these CTs combined a primary outcome relating to safety with another relating to intervention efficacy. CARDS CTs included multiple primary outcomes, which is likely to be due to CT stages being combined due to the urgent need for new treatments with more CTs in phases 1 and 2 compared with those only in phase 1.
The significance of the primary (figure 3B) and secondary (figure 3C) outcomes was next considered for both ARDS and CARDS CTs. Of the CTs with published data, three CARDS and three ARDS CTs reported that the intervention tested significantly altered one or more of the primary outcomes assessed. This result translated to a higher percentage of CARDS CTs reporting significant results compared with ARDS CTs (50% vs 36%). None of them reported that the intervention significantly altered all of the secondary outcomes; however, three ARDS and two CARDS CTs reported that the intervention significantly altered one or more of them. This result may be explained by most CTs having had a higher number of secondary outcomes than primary outcomes, so it was less likely that an intervention would significantly affect all of them.
Given the wide variety of pathophysiologic pathways involved in ARDS, a diverse range of drug families were investigated as possible treatments (figure 3D). Antithrombotics, anticoagulants, NMBAs, surfactants and biologics were under investigation for ARDS and CARDS. Sedatives, statins, carbon monoxide (CO), bronchodilators, nutritional supplements and volume expanders were being tested for ARDS but not CARDS. An antifibrotic was under investigation for CARDS but not ARDS. The most common interventions in both ARDS and CARDS were biologics (figure 3E). In this case, monoclonal antibodies (mAbs), peptides, MSCs, immunomodulators and growth factors were assessed in both conditions, while T-cell therapy was assessed in CARDS only.
Interventions demonstrating significant clinical benefit
A summary of the interventions exhibiting significant benefit to CARDS and/or ARDS patients is shown (table 2); some of the most interesting findings in terms of patient outcomes and/or clinical measures are noted, while a summary of interventions that exhibit unknown or no effect for both CARDS and ARDS patients can be found in the Electronic Supporting Information.
The mAb CERC-002 (NCT04412057) inhibits lymphotoxin-like, inducible protein (LIGHT), a cytokine within the tumour necrosis factor (TNF) family, which induces the release of other inflammatory cytokines, including granulocyte-macrophage colony-stimulating factor.38 40 This CT reported a statistically significant increase in the number of subjects alive and free of respiratory failure at day 28 of CERC-002 treatment (83.9% vs 64.5%; p=0.0440).38
NCT02097641 assessed the administration of an allogeneic bone marrow-derived human MSC infusion to ARDS patients. The primary outcome determined that no infusion-associated adverse events occurred in either the drug arm (n=40) or placebo arm (n=20). Mortality was higher in the MSC infusion group (37.5% vs 25%), but the difference was not statistically significant. However, there was a statistically significant reduction in plasma angiopoietin-2 concentration, a biomarker of pulmonary vascular injury, in the MSC infusion group. Study limitations affected the depth of conclusions, despite improvements to oxygenation seen in the MSC infusion group.52 NCT04355728 assessed the safety and efficacy of an infusion-containing human-umbilical cord-derived MSCs to COVID-19-induced ALI/ARDS patients. The incidence of adverse events was significantly reduced in the treatment group (2 vs 8 events; p=0.04), but no other outcomes were significantly improved.
NCT01597635 investigated the safety of GSK2586881, a recombinant human angiotensin-converting enzyme-2 (ACE2) peptide in ALI or ARDS, to modify the renin–angiotensin system (RAS) and alleviate disease pathology. Primary outcome measure analysis revealed that the peptide was safe, with no significant difference in adverse events in the treatment versus control group, although the basal rate of adverse events remained high. The pharmacokinetic and pharmacodynamic objectives were met in a planned futility analysis (n=39). The study was not powered to detect changes in clinical outcomes or acute physiology; however, a non-significant decrease in plasma IL-6 concentration compared with the placebo was observed.53
Treatment with an alteplase bolus (NCT04357730) led to statistically significant improvements in PaO2/FiO2 ratios, a measure of oxygenation compared with untreated controls. At 24 hours, controls (n=17) exhibited a median PaO2/FiO2 ratio of 146.7, compared with the median ratio of 144 in the intervention group (n=19; p>0.05), hence showing higher oxygenation levels. However, at 48 hours, the median values were 125 and 157.1, respectively, which translated into a statistically significant improvement when compared over 168 hours from baseline (p<0.017).54A PaO2/FiO2 ≥200 or a 50% increase in the ratio was observed in two control participants (11.8%) and nine interventional participants (47.4%), indicating a therapeutic effect of the treatment (p=0.03).54
Therapeutics effective in treating CARDS that have an unknown effect in treating ARDS
The present systematic review has identified a range of therapies assessed for their effectiveness in both ARDS and CARDS, and it has highlighted several treatments that at the time of the study in March 2022 showed therapeutic efficacy in CARDS with potential in the treatment of ARDS (table 2, interventions marked *). The marked expansion in testing of anti-inflammatory biologics for the treatment of both conditions is likely because inflammation has been identified as part of the detrimental pathology of CARDS.38 40 42 This link provided, in part, the motivation for us to review which treatments developed for CARDS, following the onset of the pandemic, also show potential in the treatment of ARDS, when developed from other illnesses.
A mAb was inferred to have favourable effects in CARDS that may be applicable to ARDS. CERC-002 significantly increased the number of CARDS patients free of respiratory failure by day 28 (NCT04412057).40 CERC-002 inhibits LIGHT, which drives inflammation, T-cell proliferation and cytokine release, contributing to tissue damage and fibrosis.38 40 LIGHT levels are raised in COVID-19 patients and serum concentration is proportional to infection severity, hence its inhibition may mitigate propagation of the cytokine storm and CARDS progression. The addition of CERC-002 to ARDS standard care may also improve patient outcomes,38 particularly in conditions such as bacterial sepsis, where LIGHT levels are raised.55
C5 is a major component of the complement cascade and is positively associated with COVID-19 infection severity.56 C5a has additional prothrombotic actions and upregulates neutrophil extracellular trap (NET) formation, which directly damages alveolar and epithelial cells, inducing cell death.12 57 Ravulizumab, a mAb trialled in COVID-19 ALI/ARDS achieved terminal inhibition of the complement system, which was thought to prevent disease progression (NCT04369469).56 However, this CT was terminated for futility, since this did not translate into positive clinical outcomes and instead increased mortality. When considering the hyperimmune response during a COVID-19 infection, however, and the variable nature of ARDS, timing of complement inhibition is crucial. Complement activation may be beneficial in the first week of the disease but have devastating outcomes as the condition progresses. Thus, Ravulizumab may be a successful therapy only in the second or third weeks of CARDS or ARDS.58
Despite the association of CARDS with a pro-coagulant phenotype, and higher thromboembolic disease manifestations than ARDS,23 31 thromboembolic complications remain a common cause of death in ARDS patients.22 Tissue plasminogen activators such as alteplase (NCT04357730) and tenecteplase (NCT00431379) may be more efficacious than traditional thrombolytic therapies, as they exhibit higher specificity yet have a comparable bleeding risk. By activating plasmin, these agents degrade fibrin, which accumulates and deposits in the pulmonary vasculature in a similar way in both CARDS and ARDS, leading to fibrosis and clot formation.31 59 Alteplase administration significantly improved PaO2/FiO2 ratios in CARDS patients by dissolving thrombi to increase blood flow (NCT04357730), also inferring potential efficacy in ARDS.54
Therapeutics effective in treating both CARDS and ARDS
The present review has also identified several therapies that show efficacy in both ARDS and CARDS (table 2, interventions marked **). MSCs are being investigated in both ARDS (NCT02804945, NCT02097641) and CARDS (NCT04345601, NCT04629105, NCT04490486, NCT04384445, NCT04355728, NCT04371393, NCT04798716, NCT04399889, NCT04905836, NCT03042143) and have shown therapeutic potential by facilitating greater increases in oxygenation following higher viability infusions (NCT02097641, NCT04355728). These trials indicate that MSC infusions can lead to a reduction in inflammatory and immunological responses following trauma such as VILI, resulting in improved lung function.44 Although immunomodulatory effects of MSCs may be particularly applicable to CARDS, by inhibiting T-cell production of proinflammatory cytokines,29 44 anti-inflammatory effects may suppress ARDS progression. Additionally, CARDS research may lead to advances in MSC isolation and culture to overcome current limitations around viability, purity and specificity.44 52
Therapeutics effective in treating ARDS that have an unknown effect in treating CARDS
Lastly, the present review has identified agents that may show benefit in ARDS but at the time of the study in March 2022 had not resolved and known effect in CARDS (table 2, interventions marked ***). These were anticoagulants (NCT00112164, NCT04397510), CO (NCT04870125, NCT02425579, NCT03799874), cyclic adenosine monophosphate (cAMP) level modification factors (NCT00434993, NCT01274481, NCT04417036), vasoactive intestinal peptide (NCT00004494, NCT04360096) and RAS modification (NCT01597635, NCT04778059).
Besides their principal roles as anticoagulants, activated protein C (NCT00112164) and heparin (NCT04397510) may have anti-inflammatory actions that improve alveolar-capillary injury. Preclinical studies with heparin have demonstrated anti-inflammatory effects, but to date, these have not translated into improved patient outcomes. There is speculation that heparin may decrease cytokine levels implicated in cytokine storm in CARDS.25 59 Such effects would likely result in an overall improvement in patient outcomes.
CO has vasoactive, antithrombotic and anti-inflammatory actions and can decrease levels of proinflammatory cytokines and increase anti-inflammatory cytokines. Experimental data suggest that CO may contribute to the resolution of pulmonary inflammation, and it may be particularly effective in ARDS that coexists with sepsis or organ dysfunction.60 Despite being shown to be safely administered in controlled research-based environments, its safety aspects remain a concern given the widely known toxicity of this gas (NCT04870125, NCT03799874, NCT02425579).60
Adrenomedullin raises intracellular cAMP levels in endothelial cells to maintain endothelial barrier integrity, so it may protect vascular function and attenuate the increase in pulmonary permeability following inflammation in conditions like ARDS.29 61 Indeed, cAMP-level modification factors show therapeutic effects in ARDS, although their side effects may limit their clinical use.62 Upregulation of plasma cAMP levels may be a novel approach to treat COVID-19 infection, potentially attenuating development of the condition.63 cAMP modification has been tested in ARDS trials with the most notable improvement in clinical measures coming from significantly improved baseline PaO2 through the use of nebulised iloprost (NCT01274481).
Vasoactive intestinal peptide is also under investigation in ARDS (NCT00004494) and CARDS (NCT04360096). The peptide is speculated to protect alveolar type II cells from inflammatory damage, preserve surfactant production and have immunomodulatory effects, such as inhibiting nuclear factor-kappa B signalling. These effects reduce production of TNF-α, interleukins and other proinflammatory cytokines, averting the cytokine storm in CARDS; these actions may also reduce or alleviate inflammation in ARDS.10 43 46
The RAS is central to pulmonary vascular tone regulation.64 65 ACE-2 cleaves angiotensin-II (Ang-II) to produce Ang1-7.29 40 47 64 65 These two products have opposing roles with Ang-II imposing vasoconstriction and Ang1-7 imposing vasodilation.29 64 65 Ang-II levels are detectably higher in ALI or ARDS (NCT01597635), thus Ang-II is believed to promote lung injury. GSK2586881, a recombinant human ACE-2 administered to ARDS patients replicated the anticipated clinical effects at the planned futility analysis (NCT01597635). GSK2586881 infusions produced a dramatic and persistent reduction in Ang-II, accompanied by a persistent elevation in Ang1-7 levels, which correlated with GSK2586681 plasma concentrations. While primary safety, and pharmacokinetic and pharmacodynamic objectives were met, a greater understanding of the role of RAS in ARDS pathophysiology is also needed (NCT01597635).47 This may be achieved by administering USB002, a pharmaceutically formulated form of Ang1-7, in CARDS (NCT04778059). However, the primary objective of this trial was to assess the safety of USB002 and the trial was terminated prematurely. Further, RAS may have differing roles in ARDS and CARDS, since the SARS-CoV-2 virus renders ACE-2 ineffective on binding (NCT04778059).64
Although several biologics were identified that did not exhibit any beneficial effects in either condition (NCT02622724, NCT00201409, NCT04616586, NCT04402060, NCT04351243), this result could in part be explained by the need for a more personalised treatment approach,31 40–42 given the widely variable nature of ARDS pathogenesis. Stratification of patients into study groups with more defined symptoms, biomarkers and/or pathological features may help to prevent the ineffective use of biologics and aid success rates, particularly where the therapeutic target is, for example, a specific inflammatory marker.40 42
In the present work, through a systematic review of freely available data from CTs, we have highlighted a number of novel and promising interventions for the treatment of CARDS as well as ARDS developed from illnesses other than COVID-19. Given their distinct but overlapping pathologies, some interventions show promise in being more efficacious in CARDS patients, such as antithrombotics and cytokine inhibitors. Personalised treatment through the increased use of biologics was identified as a promising focus of future research for ARDS as well as CARDS patients, as were complement system modifiers. Interventions such as cell-based therapies, on the other hand, have already been shown to be efficacious in both conditions, which is attributed to their broad mechanism of action and the overlap in clinical aspects of their pathologies. We also recognise that, to date, the most successful interventions for CARDS have been antiviral drugs such as remdesivir,66 Paxlovid (nirmatrelvir and ritonavir67) and molnupiravir68; however, these are unlikely to be of benefit to ARDS patients who do not have a viral infection, and CTs assessing these compounds were not identified in our searches. As ongoing CTs continue, growth of the current knowledge base will lead to a wider range of clinically approved therapies for CARDS, which, in turn, is likely to influence the future management of ARDS. Refinements in both the design of trials and selection of patient groups may facilitate trial success, and the research will surely lead to a greater understanding of the pathophysiology and optimal treatment strategy for both CARDS and ARDS.
Data availability statement
Data are available in a public, open access repository.
Patient consent for publication
Contributors EJR: methodology, investigation, formal analysis, writing—original draft and writing—review and editing; LKH: writing—original draft and writing—review and editing; RAC: conceptualisation, methodology, writing—original draft, writing—review and editing and guarantor.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.